162 related articles for article (PubMed ID: 27448968)
1. Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.
Hua L; Fang M; Dong B; Guo S; Cui C; Liu J; Yao Y; Xiao Y; Li X; Ren Y; Meng X; Hao X; Zhao P; Song Y; Wang L; Yu Y
Oncotarget; 2016 Dec; 7(50):82369-82383. PubMed ID: 27448968
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
4. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
5. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a.
Zhang J; Han X; Hu X; Jin F; Gao Z; Yin L; Qin J; Yin F; Li C; Wang Y
Mol Immunol; 2018 Nov; 103():144-155. PubMed ID: 30268986
[TBL] [Abstract][Full Text] [Related]
6. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
[TBL] [Abstract][Full Text] [Related]
7. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
8. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
Zhu M; Huang Y; Bender ME; Girard L; Kollipara R; Eglenen-Polat B; Naito Y; Savage TK; Huffman KE; Koyama S; Kumanogoh A; Minna JD; Johnson JE; Akbay EA
Cancer Res; 2021 Apr; 81(7):1813-1826. PubMed ID: 33495232
[TBL] [Abstract][Full Text] [Related]
9. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
[TBL] [Abstract][Full Text] [Related]
11. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
12. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
13. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
Takaki R; Hayakawa Y; Nelson A; Sivakumar PV; Hughes S; Smyth MJ; Lanier LL
J Immunol; 2005 Aug; 175(4):2167-73. PubMed ID: 16081783
[TBL] [Abstract][Full Text] [Related]
14. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.
Baragaño Raneros A; Martín-Palanco V; Fernandez AF; Rodriguez RM; Fraga MF; Lopez-Larrea C; Suarez-Alvarez B
Genes Immun; 2015; 16(1):71-82. PubMed ID: 25393931
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.
Codo P; Weller M; Meister G; Szabo E; Steinle A; Wolter M; Reifenberger G; Roth P
Oncotarget; 2014 Sep; 5(17):7651-62. PubMed ID: 25277195
[TBL] [Abstract][Full Text] [Related]
16. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
[TBL] [Abstract][Full Text] [Related]
17. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
18. Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.
Weinger JG; Plaisted WC; Maciejewski SM; Lanier LL; Walsh CM; Lane TE
Stem Cells; 2014 Oct; 32(10):2690-701. PubMed ID: 24898518
[TBL] [Abstract][Full Text] [Related]
19. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
20. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.
Paschen A; Baingo J; Schadendorf D
Eur J Cell Biol; 2014; 93(1-2):49-54. PubMed ID: 24629838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]